B
Biomind Labs Inc
NEO:BMND
Biomind Labs Inc
NEO:BMND
Price:
0.195
CAD
875%
Market Closed
Market Cap:
CA$15.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
B
|
Biomind Labs Inc
NEO:BMND
|
CA |
|
G
|
Grandshores Technology Group Ltd
HKEX:1647
|
SG |
|
R
|
Riot Platforms Inc
SWB:AP4N
|
US |
|
U
|
United Utilities Group PLC
F:UUEC
|
UK |
|
M
|
Moj SA
WSE:MOJ
|
PL |
|
Shandong Fiberglass Group Co Ltd
SSE:605006
|
CN |
|
A
|
Asia Pac Financial Investment Company Ltd
HKEX:8193
|
HK |
|
ZOA Corp
TSE:3375
|
JP |
|
K
|
Kingsgate Consolidated Ltd
OTC:KSKGF
|
AU |
|
C
|
Club de Polo y Equitacion San Cristobal SA
SGO:POLO
|
CL |
|
Bauhaus International (Holdings) Ltd
HKEX:483
|
HK |
|
TBI Motion Technology Co Ltd
TWSE:4540
|
TW |
|
Z
|
Zhejiang Kingland Pipeline and Technologies Co Ltd
SZSE:002443
|
CN |
|
N
|
Nanjing Railway New Technology Co Ltd
SZSE:301016
|
CN |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of BMND.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BMND
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
BMND Competitors Multiples
Biomind Labs Inc Competitors
Biomind Labs Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
B
|
Biomind Labs Inc
NEO:BMND
|
15.1m CAD | 0 | -331.7 | -65.1 | -63.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883.9B USD | 13.6 | 42.8 | 28.9 | 30.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.2B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 5.4 | 31.2 | 17.2 | 24.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 4.6 | 16.4 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.4 | 21.8 | 13.5 | 17.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.6 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161B USD | 2.6 | 20.7 | 7.9 | 10.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120B USD | 2.5 | 17 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
